Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 680-684

  Droste, J A H ^a   Verweij Van Wissen, C P W G M ^a   Kearney, B P ^b   Buffels, R ^b   VanHorssen, P J ^c   Hekster, Y A ^a   Burger, D M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GILEAD SCIENCES   (United States)

^c Farma Research BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; RIFAMPICIN; TENOFOVIR DISOPROXIL;

ABDOMINAL DISEASE; ADULT; AIDS RELATED COMPLEX; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SAFETY; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; PRIORITY JOURNAL; RASH; SOMNOLENCE; TUBERCULOSIS;

ADENINE; ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RIFAMPIN; SPECTROMETRY, FLUORESCENCE;

EID: 12944284655     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.680-684.2005     Document Type: Article

References (20)

1. Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-2739.
2. Borin, M. T., J. H. Chambers, B. J. Carel, S. Gagnon, and W. W. Freimuth. 1997. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. 61:544-553.
3. Bowen, E. F., P. S. Rice, N. T. Cooke, R. J. Whitfield, and C. F. Rayner. 2000. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 356:1488-1489.
4. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
5. Cundy, K. C., C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J. P. Shaw. 1998. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl] adenine (PMPA) in dogs. Antimicrob. Agents Chemother. 42:687-690.
6. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. O. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
7. Douglas, J. G., and M. J. McLeod. 1999. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin. Pharmacokinet. 37:127-146.
8. Finch, C. K., C. R. Chrisman, A. M. Baciewicz, and T. H. Self. 2002. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162: 985-992.
9. Greiner, B., M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. 1999. The role of intestinal P-glycoprotein in the interaction of digosin and rifampin. J. Clin. Investig. 104:147-153.
10. Justesen, U. S., A. B. Andersen, N. A. Klitgaard, K. Brosen, J. Gerstoft, and C. Pedersen. 2004. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin. Infect. Dis. 38:426-429.
11. Kearney, B. P., J. F. Flaherty, and J. Shah. 2004. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43:595-612.
12. la Porte, C. J., E. P. Colbers, R. Bertz, D. S. Voncken, K. Wikstrom, M. J. Boeree, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2004. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 48:1553-1560.
13. Lopez-Cortes, L. F., R. Ruiz-Valderas, P. Viciana, A. Alarcon-Gonzalez, J. Gomez-Mateos, E. Leon-Jimenez, M. Sarasanacenta, Y. Lopez-Pua, and J. Pachon. 2002. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41:681-690.
14. Msamanga, G. I., and W. W. Fawzi. 1997. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. N. Engl. J. Med. 337:849-851.
15. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
16. Polk, R. E., D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. S. Symonds, Y. Lou, D. Kristoff, and D. S. Stein. 2001. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob. Agents Chemother. 45:502-508.
17. Ribera, E., L. Pou, R. M. Lopez, M. Crespo, V. Falco, I. Ocana, I. Ruiz, and A. Pahissa. 2001. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J. Acquir. Immune Defic. Syndr. 28:450-453.
18. Schluger, N. W. 1999. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 28:130-135.
19. van Gelder, J., S. Deferme, L. Naesens, E. De Clercq, M. G. van den, R. Kinget, and P. Augustijns. 2002. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 30:924-930.
20. Williams, R. L., M. L. Chen, and W. W. Hauck. 2002. Equivalence approaches. Clin. Pharmacol. Ther. 72:229-237.